Liquid Stable Kit Determines Homocysteine in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Jun 2012 |
A liquid stable homocysteine kit provides a convenient and accurate method for the determination of homocysteine in human serum and plasma. Homocysteine is an indicator of a number of disease markers and should be an integral part of a laboratory’s testing menu.
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Produced by the demethylation of methionine, homocysteine is converted by vitamins B6, B12, and folic acid into useful substances. If the body is suffering from a lack of these nutrients, the process of homocysteine conversion is affected and levels rise. Elevated levels of homocysteine (Hyperhomocysteinemia) are a risk factor for a number of health problems including cardiovascular disease (CVD), stroke, dementia, complicated pregnancy, and osteoporosis.
Low levels of this analyte can also prove to be detrimental. Homocysteine is a necessary component for the production of protein and tissue within the body, therefore levels should not be lower than 5 µmol/L.
The Randox (Crumlin, United Kingdom) kit can aid in the diagnosis of both elevated and depleted levels of homocysteine and the diverse range of potential health problems associated with these.
The kit has liquid ready-to-use reagents requiring no preparation for ease of use and the elimination of reconstitution errors. It includes standards for optimal user convenience. The good on-board stability of 28 days minimizes reagent waste. The measuring range of 1.74 µmol/L to 47.9 µmol/L, allows both normal and abnormal values to be accurately measured. There is limited interference from bilirubin, haemoglobin, intralipids, and triglycerides, enabling optimum performance and the generation of precise, reliable results. A correlation coefficient of 0.98 was obtained against another commercially available kit. Protocols are available for a range of analyzers.
Related Links:
Randox
Latest Clinical Chem. News
- Common Kidney Function Tests May Miss CKD in Cancer Patients
- Point-of-Care Blood Biomarker Test Detects Brain Injury Missed by CT
- Daily Blood Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
- Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis
- Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
- Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
- Study Links Saliva-Based Epigenetic Signals to OCD Treatment Outcomes
- New One-Step Syphilis Test Could Enable Earlier Detection and Faster Treatment
- Multimodal Clinical Data Models Predict Cachexia Risk Across Cancers
- Study Evaluates Alzheimer’s Blood Biomarker Across Racial and Ethnic Groups
- Blood Protein May Help Identify Treatment-Resistant Psychosis
- Electrochemical Biosensor Rapidly Detects Cerebrospinal Fluid Leaks
- Blood Protein Panel Supports Monitoring of Treated Celiac Disease
- Hemoglobin Levels May Help Signal Long-Term Dementia Risk
- Liquid Biopsy Platform Shows Promise for Early Gynecologic Cancer Detection
- Global Survey Finds Pediatric Troponin Testing Lacks Consistent Reference Intervals
Channels
Molecular Diagnostics
view channel
Six-Gene Score Improves Prognosis Prediction in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a blood cancer with outcomes that can vary widely from one patient to another. This variability complicates prognosis despite the laboratory information available from bone... Read moreLong-Read Sequencing Reveals Cancer-Driving Changes Missed by Conventional Testing
Cancer diagnosis often relies on identifying genomic alterations that influence tumor behavior and treatment selection. However, conventional short-read sequencing can miss complex DNA changes, leaving... Read more
Whole-Genome MRD Test Detects Traces of Cancer During and After Treatment
Small amounts of cancer can remain after treatment at levels that are difficult to detect, creating uncertainty about recurrence risk. Molecular residual disease (MRD) testing addresses this challenge... Read more
Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use
Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read moreHematology
view channel
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows
Molecular laboratories rely on nucleic acid analysis to detect molecular information accurately and reproducibly across a wide range of applications. Supporting these routine workflows, a newly launched... Read more
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read moreIndustry
view channel
Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
For many patients, cancer treatment does not eliminate the risk of recurrence, which may occur months or years later and become harder to treat after spreading. Recurrence is often detected only after... Read more







